By Editor • September 4, 2026 • 1 min read
Novartis' pelacarsen, an experimental drug for heart disease, failed to show efficacy in a pivotal study, disappointing hopes for a new treatment.
Read moreBy Editor • September 1, 2026 • 1 min read
Novartis makes strides in multiple sclerosis treatment with a new BTK inhibitor, while Alumis faces setbacks in lupus trials.
Read moreBy Editor • August 29, 2026 • 1 min read
Novartis' drug pacibekitug shows promise in lowering inflammation, raising hopes for cardiovascular treatment advancements.
Read moreBy Editor • August 26, 2026 • 1 min read
Drugmakers are targeting Lp(a), a genetic cardiovascular risk factor, with new treatments in late-stage trials, including efforts from Novartis.
Read moreBy Editor • August 18, 2026 • 1 min read
Eyepoint's trial setback for Duravyu contrasts with Ocular Therapeutix's stock rise, while Novartis withdraws reimbursement plans for another new drug in Canada.
Read more
